CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 334 enrolled
Drug / intervention
Fluoxetine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00018902
NCT00018902Phase 3Completed
CompareCT.gov

Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)

University of Pittsburgh·interventional·Posted Jul 12, 2001·Updated Mar 12, 2014

In Brief

A Phase 3 clinical trial evaluating Fluoxetine, Venlafaxine, and 2 other interventions for Depression. Completed, enrolled 334 participants across 6 sites.

Detailed Summary

The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 12, 2001
Enrollment StartJan 1, 2001
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 25.0 years ago

Interventions

Fluoxetinedrug

Standard anti-depressant treatment with the SSRI fluoxetine

Venlafaxinedrug

Standard antidepressant treatment with the non-SSRI medication venlafaxine

Cognitive Behavioral Therapy (CBT)behavioral

CBT addresses maladaptive beliefs in order to encourage behavioral change

Citalopramdrug

Standard anti-depressant treatment with the SSRI fluoxetine